

References

1. **Appleton CP, Jensen JL, Hatle LK and Oh JK.** Doppler evaluation of left and right ventricular diastolic function: a technical guide for obtaining optimal flow velocity recordings. *J Am Soc Echocardiogr* 1997; 10:271–292.
2. **Arnlov J, Evans JC, Meigs JB, et al.:** Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. *Circulation* 2005; 112:969.
3. **Asbun J and Villarreal FJ:** The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. *J Am Coll Cardiol* 2006; 47:693.
4. **Ashrafian H, Frenneaux MP and Opie LH:** Metabolic mechanisms in heart failure. *Circulation* 2007; 116:434.
5. **Asselbergs FW, Diercks GF, Hillege HL, et al.:** Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. *Circulation* 2004; 110:2809.
6. **Azevedo CF, Amado LC, Kraitchman DL, Gerber BL, Osman NF, Rochitte CE, et al.** Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging. *Eur Heart J* 2004; 25:1419-27.
7. **Bakris GL, Ruilope L, Locatelli F, et al.:** Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. *Kidney Int* 2007; 72:879.

8. **Bakris GL, Williams M, Dworkin L et al.** Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. *Am J Kidney Dis* 2000; 36: 646±61.
9. **Barzilay JI, Peterson D, Cushman M, et al.:** The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: The cardiovascular health study. *Am J Kidney Dis* 2004; 44:25.
10. **Baykan, Erdogan T, Erem C et al,** The relationship between flow-mediated dilatation and left ventricular function in type 2 diabetic patients with microalbuminuria, *Endocrine*. 2006 Oct; 30 (2):197-202.
11. **Bell SP, Nyland L, Tischler MD, et al.** Alterations in the determinants of diastolic suction during pacing tachycardia. *Circ Res*. 2000; 87(3):235–240.
12. **Bertoni AG, Hundley WG, Massing MW, et al.:** Heart failure prevalence, incidence, and mortality in the elderly with diabetes. *Diabetes Care* 2004; 27:699-703.
13. **Bhatia V, Wilding GE, Dhindsa G, Bhatia R, Garg RK, Bonner AJ, Dhindsa S.** Association of poor glycemic control with prolonged hospital stay in patients with diabetes admitted with exacerbation of congestive heart failure. *Endocr Pract* 2004; 10:467–471.
14. **Boersma E, Poldermans D, Bax JJ, et al.** DECREASE Study Group (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography). Predictors of cardiac events after major vascular surgery: role of clinical characteristics,

- dobutamine echocardiography, and beta-blocker therapy. *JAMA* 2001; 285:1865–1873.
- 15. Boudina S, Abel ED.** Diabetic cardiomyopathy revisited. *Circulation* 2007; 115:3213–3223.
- 16. Boulware LE, Jaar BG, Tarver-Carr ME, et al.:** Screening for proteinuria in US adults: a cost-effectiveness analysis. *JAMA* 2003; 290:3101.
- 17. Brantsma AH, Attobari J, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT:** What causes progression and regression of urinary albumin excretion in the general population. *J Am Soc Nephrol* 16, 324A, 2005.
- 18. Brenner E, Cooper M, de Zeeuw D, Keane W, Mitch W, Parving H, Remuzzi G, Snapinn S, Zhang Z, and Shahinfar S.** Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 345: 2001, 861-869.
- 19. Cai L, Wang Y, Zhou G, et al.** Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. *J Am Coll Cardiol* 2006; 48:1688.
- 20. Caramori M, Fioretto P, and Mauer M.** The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? *Diabetes* 49: 2000, 1399-1408.
- 21. Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlof B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z.** Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. *Am J Cardiol* 2005;96: 1530–1536.

- 22.Carter JL, Tomson CR, Stevens PE, Lamb EJ:** Does urinary tract infection cause proteinuria or microalbuminuria? A systematic review. *Nephrol Dial Transplant* 2006; 21:3031.
- 23.Clausen P, Jensen JS, Jensen G, et al.:** Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. *Circulation* 2001; 103:1869.
- 24.Cohen GI, Pietrolungo JF, Thomas JD, Klein AL.** A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. *J Am Coll Cardiol* 1996; 27:1753–1760.
- 25.Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW,Lacher DA, Hostetter TH:** Chronic kidney disease awareness, prevalence, and trends among US adults, *J Am Soc Nephrol* 16: 180–188, 2005.
- 26.Cosson E, Pham I, Valensi P, et al.:** Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries. *Diabetes Care* 2006; 29:107.
- 27.Cosson S, Kevorkian JP.** Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? *Diabetes Metab* 2003; 29(5):455-66.
- 28.Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG.** Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: An integrated index of vascular function? *Circulation* 2002; 106: 2085-90.
- 29.Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML,** on behalf of the EUROPA investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients

- with diabetes in the EUROPA study: results from the PERSUADE substudy. *Eur Heart J* 2005; 26:1369–1378.
- 30.Dargie HJ, Hildebrandt PR, Riegger GA, et al.:** A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. *J Am Coll Cardiol* 2007; 49:1696.
- 31.De Zeeuw D, Parving HH, Henning RH:** Microalbuminuria as an early marker for cardiovascular disease. *J Am Soc Nephrol* 17: 2006, 2100–2105.
- 32.De Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Shahinfar S, et al.** Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation* 2004; 110: 921 -7.
- 33.Deswal A, Petersen NJ, Soucek J, Ashton CM, Wray NP.** Impact of race on health care utilization and outcomes in veterans with congestive heart failure. *J Am Coll Cardiol* 2004; 43:778–784.
- 34.Devereux RB, Roman MJ, Paranicas M, et al.:** Impact of diabetes on cardiac structure and function: the strong heart study. *Circulation* 2000; 101:2271.
- 35.Devereux RB, Roman MJ, Paranicas M, Lee ET, Welty TK, Fabsitz RR et al.:** A populationbased assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. *Am.Heart J.* 2001; 141:439-46.
- 36.De Zeeuw D, Remuzzi G, Parving HH, et al.** Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. *Kidney Int.* 2004; 65:2309–2320.

- 37.Diercks GF, Hillege HL, van Boven AJ, et al.:** Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. *J Am Coll Cardiol* 2002; 40:1401.
- 38.Di Bello V, Talarico L, Picano E, Di Muro C, Landini L, Paterni M, et al.** Increased echodensity of myocardial wall in the diabetic heart: an ultrasound tissue characterization study. *J Am Coll Cardiol* 1995;25:1408-1.
- 39.Dilsizian V:** SPECT and PET techniques. In: Dilsizian V, Narula J, Braunwald E, ed. Atlas of Nuclear Cardiology, Philadelphia: *Current Medicine*; 2003:131-146.
- 40.Dormandy JA, Charbonnel B, Eckland DJ, et al.:** Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005; 366:1279.
- 41. Duman, Refik Demirtunç*, Bilgehan Karadağ, Meryem Karatafl et al ,** association of albuminuria with impaired aortic elasticity and left ventricular diastolic dysfunction in type 2 diabetes *Anadolu Kardiyol Derg* 2008; 8: 10-5.
- 42.Dries DL, Sweitzer NK, Drazner MH, et al.:** Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. *J Am Coll Cardiol* 2001; 38:421.
- 43.Eknoyan G, Hostetter T, Bakris GL, et al.** Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). *Am J Kidney Dis* 2003; 42:617.

- 44. Eiskjaer H, Bagger JP, Mogensen CE, Schmitz A, Pedersen EB:** Enhanced urinary excretion of albumin in congestive heart failure: effect of ACE-inhibition. *Scand J Clin Lab Invest* 2006; 52:193-99.
- 45. Elisaf M, Mikhailidis DP:** Statins and renal function. *Angiology* 53:493–502, 2002.
- 46. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliari L, Ceriello A, and Giugliano D.** Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation* 106:2002, 2067-2072.
- 47. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:** Follow up report on the diagnosis of diabetes mellitus. *Diabetes Care* 26: 2003, 3160– 3167.
- 48. Fang ZY, Prins JB, Marwick TH.** Diabetic cardiomyopathy. *Endocr Rev* 2004; 25:543-67.
- 49. Feigenbaum H, Zaky A, Nasser WK.** Use of ultrasound to measure left ventricular stroke volume. *Circulation* 1967; 38: 1092-2099.
- 50. Fein FS.** Diabetic cardiomyopathy. *Diabetes Care*, 1990, 13, 1169-1179.
- 51. Fieno DS, Hillenbrand HB, Rehwald WG, Harris KR, Decker RS, Parker MA, Klocke FJ, Kim RJ, Judd RM.** Infarct resorption, compensatory hypertrophy, and differing patterns of ventricular remodeling following myocardial infarctions of varying size. *J Am Coll Cardiol* 2004; 43:2124–2131.
- 52. Fletcher GF, Balady GJ, Vogel RA:** Preventive cardiology: How can we do better? 33rd Bethesda Conference. *J Am Coll Cardiol* 2002; 40:579.

- 53.Freedman BI, Langefeld CD, Lohman KK, et al.:** Relationship between albuminuria and cardiovascular disease in type 2 diabetes. *J Am Soc Nephrol* 2005; 16:2156.
- 54.Freire CMV. Avaliação da função diastólica do ventrículo esquerdo em pacientes com diabetes gestacional, no terceiro trimestre de gestação e no pós-parto. (Mestrado). UFMG, 2005. 45: 198– 202.**
- 55.Foster MC, Hwang SJ, Larson MG, Parikh NI, Meigs JB, Vasan RS,Wang TJ, Levy D, Fox CS:** Cross-classification of microalbuminuria and reduced glomerular filtration rate: Associations between cardiovascular disease risk factors and clinical outcomes. *Arch Intern Med* 167: 1386–1392, 2007.
- 56.Galderisi M:** Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. *J Am Coll Cardiol* 2006; 48:1548.
- 57.Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM:** Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. *Kidney Int.* 2002; 61:2165-75.
- 58.Germano G, Borer JS, Berman DS:** Myocardial function assessment by nuclear techniques. In: Dilsizian V, Narula J, Braunwald E, ed. Atlas of Nuclear Cardiology, 2nd ed. Philadelphia: *Current Medicine*; 2006.
- 59.Gerstein HC, Mann JF, Yi Q et al.** Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001; 286: 421±26.
- 60.Gillebert TC, Van de Veire N, De Buyzere ML, De Sutter J.** Time intervals and global cardiac function. Use and limitations. *Eur Heart J* 2004; 25:2185–2186.

- 61.Ginsberg JM, Chang BS, Matarese RA, Garella S:** Use of single voided urine samples to estimate quantitative proteinuria. *N Engl J Med* 1983; 309:1543.
- 62.Givertz MM, Colucci WS, Braunwald E.** Clinical aspects of heart failure; pulmonary edema, high-output failure. In: Braunwald's heart disease: a textbook of cardiovascular medicine, 7th ed. Zipes DP, Libby P, Bonow RO, Braunwald E (eds). Philadelphia: Elsevier Saunders 2005; 539–568.
- 63.Gopal, AS, Shen, Z, Sapin, PM, et al.** Assessment of cardiac function by three-dimensional echocardiography compared with conventional noninvasive methods. *Circulation* 1995; 92:842.
- 64.Gosling P.** Microalbuminuria: a marker of systemic disease. *Br J Hosp Med* 1995; 54: 285±90.
- 65.Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC.** Predictors Relation between chronic heart failure and diabetes mellitus 1235 of congestive heart failure in the elderly: The Cardiovascular Health Study. *J Am Coll Cardiol* 2000; 35:1628–1637.
- 66.Grandi AM, Piantanida E, Franzetti I, Bernasconi M, Maresca A, Marnini P, et al.** Effect of glycemic control on the left ventricular diastolic function in type 1 diabetes mellitus. *Am J Cardiol* 2006; 97:17-76.
- 67.Grossman W:** Evaluation of systolic and diastolic function of the myocardium.In: Baim DS, ed. Cardiac Catheterization, Angiography, and Intervention, 7th ed. *Baltimore: Williams & Wilkins; 2006:315-320.*
- 68.Haas SJ, Vos T, Gilbert RE, Krum H.** Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without

- diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. *Am Heart J* 2003;146:848–853.
- 69. Haffner SM**, Management of dyslipidemia in adults with diabetes. *Diabetes Care* 1998, 21:160-178
- 70. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK.** Risk factors for congestive heart failure in US men and women: NHANES-I epidemiologic follow-up study. *Arch Intern Med* 2001; 161:996–1002.
- 71. Held C, Gerstein HC, Yusuf S, et al.:** Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. *Circulation* 2007; 115:1371.
- 72. Henry RM, Kostense PJ, Spijkerman AM, et al.** Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. *Circulation* 2003;107:2089-95.
- 73. Hillege HL, Fidler V, Diercks GF, et al.:** Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation* 2002; 106:1777.
- 74. Hoy WE, Wang Z, VanBuynder P, Baker PR, Mathews JD.** The natural history of renal disease in Australian Aborigines, part 1: changes in albuminuria and glomerular filtration rate over time. *Kidney Int.* 2001; 60(1):243-248.
- 75. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al.** ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: developed in collaboration with the International Society for Heart and Lung Transplantation; *Circulation* 2001; 104(24):2996-3007.
- 76. Ibsen H, Olsen MH, Wachtell K, et al.:** Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive

- patients: losartan intervention for endpoint reduction in hypertension study. *Hypertension* 2005; 45:198.
- 77.Ibsen H, Wachtell K, Olsen MH, et al.:** Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. *J Hypertens* 2004; 22:1805.
- 78.Ilercil A, Devereux RB, Roman MJ, et al.** Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study. *Diabetes* 2002; 51:1543-7.
- 79.Imitani I, Jain D, Joska TM, et al:** Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiology in the current era. *J Nucl Cardiol* 2003; 10:132.
- 80.Iribarren C, Karter AJ, Go AS, et al.:** Glycemic control and heart failure among adult patients with diabetes. *Circulation* 2001; 103:2668.
- 81.Janardhanan R, Dwivedi G, Hayat S, Senior R.** Myocardial contrast echocardiography: a new tool for the assessment of myocardial perfusion. *Ind Heart J* 2005; 57:210–216.
- 82.Jefferson JG, Greene SA, Smith MA, et al.:** Urine albumin to creatinine ratio — response to exercise in diabetes. *Arch Dis Child* 1985; 60:305.
- 83.Jenkins, C, Bricknell, K, Hanekom, L, Marwick, TH.** Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. *J Am Coll Cardiol* 2004; 44:878.
- 84.Jennifer E. Liu,David C. Robbins,et al.** Albuminuria and LV Dysfunction in Type 2 Diabetes, *JACC* 2003, Vol.41, 2003:2022.

- 85. Jensen S.** Microalbuminuria and risk of atherosclerosis. Clinical epidemiological and physiological investigators. *Dan Med Bull* 2000; 47(2): 63–78.
- 86. Joanne, J. Wouter Jukema, et al.** Noninvasive Angiography and Assessment of Left Ventricular Function Using Multislice Computed Tomography in Patients With Type 2 Diabetes. *Diabetes Care* 2004; 27:2905–2910.
- 87. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, Kusek JW, Byrd-Holt D, Narayan KM, Herman WH, Jones CP, Salive M, Agodoa LY:** Microalbuminuria in the US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 39: 445–459, 2002.
- 88. Kalra DK, Ramchandani M, Zhu X, Lawrie G, Reardon MJ, Mann DL, Zoghbi WA, Nagueh SF.** Relation of tissue Doppler-derived myocardial velocities to serum levels and myocardial gene expression of tumor necrosis factor-alpha and inducible nitric oxide synthase in patients with ischemic cardiomyopathy having coronary artery bypass grafting. *Am J Cardiol* 2002;90: 708-12.
- 89. Karalliedde J, Viberti G:** Microalbuminuria and cardiovascular risk. *Am J Hypertens* 17: 2004, 986–993.
- 90. Keane WF.** Metabolic pathogenesis of cardiorenal disease. *Am J Kidney Dis* 2001; 23(6): 1372–1375.
- 91. Kitzman D, Sullivan MJ.** Exercise intolerance in patients with heart failure: role of diastolic dysfunction. In: Lorell BH, Grossman W, eds. *Diastolic Relaxation of the Heart, 2nd ed.* Boston: Kluwer, 1994:295.
- 92. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al.:** Very low levels of microalbuminuria are associated with increased risk

- of coronary heart disease and death independently of renal function, hypertension, and diabetes. *Circulation* 2004; 110:32.
- 93.Koch, K, Oellig, F, Oberholzer, K, et al.** Assessment of right ventricular function by 16-detector-row CT: comparison with magnetic resonance imaging. *Eur Radiol* 2005; 15:312.
- 94.Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Ryden L, Scherhag A et al.** Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). *Eur J Heart Fail* 2004; 6:467–475.
- 95.Konduracka E, Gackowski A, Rostoff P, et al.:** Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. *Eur Heart J* 2007; 28:2465.
- 96.Krüger M, dos Remedios C, Linke WA:** Titin phosphorylation by protein kinases A and G in normal and failing human hearts decreases myocardial passive stiffness. *Circulation* 2007, 116: II–301.
- 97.Kuhl, HP, Schreckenber, M, Rulands, D, et al.** High-resolution transthoracic real-time three-dimensional echocardiography: quantitation of cardiac volumes and function using semi-automatic border detection and comparison with cardiac magnetic resonance imaging. *J Am Coll Cardiol* 2004; 43:2083.
- 98.Lawson, MA, Blackwell, GG, Davis, ND, et al.** Accuracy of biplane long-axis left ventricular volume determined by cine magnetic resonance imaging in patients with regional and global dysfunction. *Am J Cardiol* 1996; 77:1098.

- 99. Leber AW, Knez A, Becker C, Becker A, White C, Thilo C, Reiser M, Haberl R and Steinbeck G:** Non-invasive intravenous coronary angiography using electron beam tomography and multislice computed tomography. *Heart* 2003; 89:633– 639.
- 100. LeWinter MM.** The isolated isovolumic (Langendorff) heart preparation. In: Hoit BD, Walsh RA, eds. *Cardiovascular Physiology in the Genetically Engineered Mouse*. 2nd ed. Norwell, MA: *Kluwer Academic Publishers*; 2002:113–127.
- 101. Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, de Zeeuw D, Hostetter TH, Lameire N, Eknoyan G:** Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improve Global Outcomes (KDIGO). *Kidney Int* 67: 2089–2100, 2005.
- 102. Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J, Ritz E, Atkins R, Rohde B, and Raz I.** Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 345: 2001, 851-860.
- 103. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE and Kristiansson K.** Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359:1004 -1010.
- 104. Liu, Jennifer E, David C. Robbins, et al.** Albuminuria and LV Dysfunction in Type 2 Diabetes. *JACC Vol. 41, No. 11, 2003, June 4, 2002–8.*
- 105. Lago RM, Singh PP, Nesto RW:** Congestive heart failure and cardiovascular death in patients with prediabetes and type 2

- diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet* 2007; 370:1129.
- 106. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G and Cohn JN.** Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. *J Am Coll Cardiol* 2002, 40:1414-1421.
- 107. Marelli D, Laks H, Patel B, et al.:** Heart transplantation in patients with diabetes mellitus in the current era. *J Heart Lung Transplant* 2003; 22:1091.
- 108. Masoudi FA, Inzucchi SE, Wang Y, et al.:** Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. *Circulation* 2005; 111:583.
- 109. Masoudi FA, Wang Y, Inzucchi SE, et al:** Metformin and thiazolidinedione use in Medicare patients with heart failure. *JAMA* 2003; 290:81.
- 110. Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T.** The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. *Diabet Med* 1995; 12: 482±87.
- 111. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G.** Prospective study of microalbuminuria as predictor of mortality in NIDDM. *Diabetes* 1992;42:736-41.
- 112. Mattock MB, Barnes DJ, Viberti GC, et al.** Microalbuminuria and coronary heart disease in NIDDM. *Diabetes* 1998; 47:1786–92.
- 113. Mimran A, Ribstein J, DuCailar G, Halimi JM.** Albuminuria in normals and essential hypertension. *J Diabetes Complications* 1994; 8: 150±56.

114. **Mogensen CE, Vestbo E, Poulsen PL, et al.:** **Microalbuminuria and potential confounders.** A review and some observations on variability of urinary albumin excretion. *Diabetes Care* 1995; 18:572.
115. **Mogyorosi A, Ziyadeh FN.** Update on pathogenesis, markers and management of diabetic nephropathy. *Curr Opin Nephrol Hypertens* 1996; 5: 243±53.
116. **Mohacsi P, Fowler MB, Krum H, Tendera M, Coats AJ, Rouleau JL, Amann-Zalan I, Holcslaw TL, Roecker EB, Packer M.** Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study. *Circulation* 2001; 104: II-754.
117. **NAIDOO .D.P,** The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. *Cardiovasc J South Afr* 2002; 13: 194-199.
118. **Nakamura Y, Myers BD:** Charge selectivity of proteinuria in diabetic glomerulopathy. *Diabetes* 1988; 37:1202.
119. **Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B.** Intensive diabetes treatment and cardiovascular disease in patients with type-1 diabetes. *N Engl J Med* 2005; 353:2643-2653.
120. **Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B:** Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care* 2007, 30:753-759.
121. **Nathan, DM, Rosenbaum, C, Protasowicki, VD.** Single-void samples can be used to estimate quantitative proteinuria. *Diabetes Care* 1987; 10:414.

122. **Nesto RW, Bell D, Bonow RO, et al.:** Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. *Circulation* 2003; 108:2941.
123. **Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB.** The incidence of congestive heart failure in type 2 diabetes: an update. *Diabetes Care* 2004; 27:1879–1884.
124. **Nieman K, Pattynama PM, Rensing BJ, van Geuns RJ, de Feyter PJ:** Evaluation of patients after coronary artery bypass surgery: CT angiographic assessment of grafts and coronary arteries. *Radiology* 2003; 229:749–756.
125. **Nosadini R, Velussi M, Brocco E, Abaterusso C, Piarulli F, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, Tonolo G:** Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenetic mechanisms. *Diabetes* 54: 2005, 228–233.
126. **Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, De Mets DL.** Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001; 344:1651–1658.
127. **Parving H, Lehnert H, Rochner-Mortensen J, Gomis R, Andersen S, and Arner P.** The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 345, 2001, 870-878.
128. **Parving H.** Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. *Diabetologia* 41: 1998, 745-759.
129. **Parving H-H, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG:** Prevalence and risk factors for microalbuminuria in a referred

- cohort of type II diabetic patients: A global perspective. *Kidney Int* 2006,69: 2057–2063.
- 130. Pedrinelli R, Giampietro O, Carmassi F, et al.:** Microalbuminuria and endothelial dysfunction in essential hypertension. *Lancet* 1994; 344:14.
- 131. Picca M, Agozzino F, Pelosi G.** Influence of microalbuminuria on left ventricular geometry and function in hypertensive patients with type 2 diabetes mellitus. *Ital Heart J* 2003; 4:48-52.
- 132. Raman, SV, Shah, M, McCarthy, B, et al.** Multi-detector row cardiac computed tomography accurately quantifies right and left ventricular size and function compared with cardiac magnetic resonance. *Am Heart J* 2006; 151:736.
- 133. Ravid M, Lang R, Rachmani R, Lishner M.** Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non insulin dependent diabetes mellitus. A 7-year follow-up study. *Arch Intern Med* 1996; 156: 286±89.
- 134. Roberto M. Lang et al.** Recommendations for Chamber Quantification. *Hypertension* 2005,45: 198–202,.
- 135. Rodrigues B, Cam MC, McNeill JH:** Myocardial substrate metabolism: implications for diabetic cardiomyopathy. *J Mol Cell Cardiol* 1995; 27:169.
- 136. Roest M, Banga JD, et al.** Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. *Circulation* 2001; 103:3057–61.
- 137. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H:** Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The

- Nord-Trondelag Health Study (HUNT), Norway. *Am J Kidney Dis* 2003, 42: 466–473.
- 138. Ropers D, Baum U, Pohle K, Anders K, Ulzheimer S, Ohnesorge B, Schlundt C, Bautz W, Daniel WG, Achenbach S:** Detection of coronary artery stenoses with thin-slice multi-detector row spiral computed tomography and multiplanar reconstruction. *Circulation* 2003; 107:664–666.
- 139. Rose BD:** Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987, pp. 11-16.
- 140. Rossen JD:** Abnormal microvascular function in diabetes: relationship to diabetic cardiomyopathy. *Coron Artery Dis* 1996; 7:133.
- 141. ROXY SENIOR:** Role of Contrast Echocardiography for the Assessment of Left Ventricular Function. *Diabetic Med.* 17 (2000) 321–325.
- 142. Rutten FH, Vonken EJ, Cramer MJ, et al.** Cardiovascular magnetic resonance imaging to identify left-sided chronic heart failure in stable patients with chronic obstructive pulmonary disease. *Am Heart J.* 2008; 156:506–12.
- 143. Salmasi AM, Jepson E, Grenfell A, Kirollos C, Dancy M.** The degree of albuminuria is related to left ventricular hypertrophy in hypertensive diabetic and is associated with abnormal left ventricular filling: a pilot study. *Angiology* 2003;54:671-8.
- 144. Sano T, Kawamura T, Matsumae H et al.** Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. *Diabetes Care* 1994; 420±24.
- 145. Schmitz A.** Microalbuminuria, blood pressure, metabolic control, and renal involvement: longitudinal studies in white non-

- insulin-dependent diabetic patients. *Am J Hypertens* 1997; 10: 189S±97S.
- 146. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD:** Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes: The EURODIAB Prospective Complications Study. *Diabetologia* 48: 2005, 370–378.
- 147. Schwab SJ, Dunn FL, Feinglos MN:** Screening for microalbuminuria. A comparison of single sample methods of collection and techniques of albumin analysis. *Diabetes Care* 1992; 15:1581.
- 148. Scognamiglio R, Avogaro A, Casara D, et al.:** Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. *J Am Coll Cardiol* 1998; 31:404.
- 149. Sengupta PP, Mohan JC, Pandian N.** Tissue Doppler echocardiography: principles and applications. *IHJ* 2002; 54 (4): 368-78.
- 150. Sharir T, Feldman MD, Haber H, et al.** Ventricular systolic assessment in patients with dilated cardiomyopathy by preload-adjusted maximal power. *Circulation* 1994;89:2045.
- 151. Shekelle PG, Rich MW, Morton SC, Atkinson C, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B.** Efficacy of angiotensin-converting enzyme inhibitors and betablockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. *J Am Coll Cardiol* 2003;41:1529–1538.

- 152. Shim, Sungha Parka, Eui-Young Choia, Seok-Min Kanga, Bong-Soo Chab, Jong-Won Haa, Se-Joong Rima, Hyun-Chul Leeb, Namsik Chung et al.** Is albuminuria an indicator of myocardial dysfunction in diabetic patients without overt heart disease? A study with Doppler strain and strain rate, *Metabolism Clinical and Experimental* 2008, 57,448–452.
- 153. Shindler DM, Kostis JB, Yusuf S, et al.:** for the SOLVD Investigators. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. *Am J Cardiol* 1996; 77:1017.
- 154. Sibley SD, Hokanson JE, Steffes MW, et al.:** Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. *Diabetes Care* 1999; 22:1165.
- 155. Singh S, Loke YK, Furberg CD:** Thiazolidinediones and Heart Failure: A teleo-analysis. *Diabetes Care* 2007; 30:2148.
- 156. Solomon SD, Bulwer B et al.,** Assessment of left ventricular function, Essential echocardiography, *Human press inc New Jersey, chapter 5, p89;117.*
- 157. Stamler J, Vaccaro O, Neaton JD, Wentworth D.** Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care*, 1993, 16,434-444.
- 158. Standards of medical care for patients with diabetes mellitus.** *Diabetes Care* 2001; 24 (suppl 1): S33±S43.
- 159. Stehouwer C, Nauta J, Zeldenrust G, Hackeng W, Donker A, and Ottolander G.** Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. *Lancet* 340: 1992, 319-323.

- 160. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW.** Endothelial dysfunction and pathogenesis of diabetic angiopathy. *Cardiovasc Res* 1997; 34: 55±68.
- 161. Stehouwer CD, Smulders YM:** Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. *J Am Soc Nephrol* 17: 2006, 2106–2111.
- 162. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E.** Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. *Diabet Med* 1995; 12: 149±55.
- 163. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR.** Association of glycaemia with macrovascular and microvascular complications of type-2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000; 321:405–412.
- 164. Sugeng, L, Mor-Avi, V, Weinert, L, et al.** Quantitative assessment of left ventricular size and function: side-by-side comparison of real-time three-dimensional echocardiography and computed tomography with magnetic resonance reference. *Circulation* 2006; 114:654.
- 165. Sungha Parka, Eui-Young Choia, Seok-Min Kanga, et al** Is albuminuria an indicator of myocardial dysfunction in diabetic patients without overt heart disease? *Metabolism Clinical and Experimental* (2008) 57, 448–452.
- 166. Suzuki Katsunori Suzuki , Kiminori Kato, Osamu Hanyu, Osamu Nakagawa, et al.** Left ventricular mass index increases in proportion to the progression of diabetic nephropathy in Type 2 diabetic patients / *Diabetes Research and Clinical Practice* 54 (2001) 173–180.

- 167. Swaminathan S, Ferrer PL, Wolff GS, Gomez- Marin O, Rusconi PG.** Usefulness of tissue Doppler echocardiography for evaluating ventricular function in children without heart disease. *Am J Cardiol* 2003; 91 (5): 570-574.
- 168. Tabata T, Thomas JD, Klein AL.** Pulmonary venous flow by Doppler echocardiography: revisited 12 years later. *J Am Coll Cardiol* 2003; 41:1243-50.
- 169. Tapp RJ, Shaw JE, Zimmet PZ, Balkau B, Chadban SJ, Tonkin AM, Welborn TA, Atkins RC:** Albuminuria is evident in the early stages of diabetes onset: Results from the Australian Diabetes, Obesity, and Lifestyle Study (Aus- Diab). *Am J Kidney Dis* 44: 792–798, 2004
- 170. Tenenbaum A, Motro M, Fisman EZ, Leor J, Freimark D, Boyko V, Mandelzweig L, Adler Y, Sherer Y, Behar S.** Functional class in patients with heart failure is associated with the development of diabetes. *Am J Med* 2003; 114:271–275.
- 171. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):** a randomized trial. *Lancet* 1999; 353:9–13.
- 172. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Ryden L.** The association between glucose abnormalities and heart failure in the population-based Reykjavik study. *Diabetes Care* 2005; 28:612–616.
- 173. Tibb AS, Ennezat PV, Chen JA, Haider A, Gundewar S, Cotarlan V, Aggarwal VS, Talreja A, Le Jemtel TH.** Diabetes lowers aerobic capacity in heart failure. *J Am Coll Cardiol* 2005; 46:930–931.

- 174. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.** UK Prospective Diabetes Study Group. *BMJ* 1998; 317: 703±13.
- 175. Tuttle KR:** Albuminuria reduction: the holy grail for kidney protection. *Kidney Int* 2007; 72:785.
- 176. Van Hoesven K, Factor S:** A comparison of the pathologic spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. *Circulation* 1990; 82:848.
- 177. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P.** Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes Hypertension CARdiovascular Events and Ramipril) study. *Diabetes Care* 2003; 26:855–860.
- 178. Wachtell K, Ibsen H, Olsen MH, et al.:** Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Ann Intern Med* 2003; 139:901.
- 179. Walter J. Paulus, et al,** The Failing Diabetic Heart, *Current Diabetes Reports* 2009, 9:79–86.
- 180. Wang CH, Weisel RD, Liu PP, et al.:** Glitazones and heart failure: critical appraisal for the clinician. *Circulation* 2003; 107:1350.
- 181. Wang TJ, Evans JC, Meigs JB, et al.:** Low-grade albuminuria and the risks of hypertension and blood pressure progression. *Circulation* 2005; 111:1370.
- 182. Wasty F, Alawi MZ, Moore S.** Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and DM. *Diabetologia* 1993; 36:316 22.

- 183. Wlodarczyk JH, Keogh A, Smith K, McCosker C.** CHART: congestive cardiac failure in hospitals, an Australian review of treatment. *Heart Lung Circ* 2003; 12:94–102.
- 184. Wu YW, Tadamura E, Kanao S, et al.** Left ventricular functional analysis using 64-slice multidetector row computed tomography: comparison with left ventriculography & MRC. *Cardiology*. 2008; 109:135–42.
- 185. Yki-Jarvinen H:** Thiazolidinediones. *N Engl J Med* 2004; 351:1106.
- 186. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV.** Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. *Circulation* 2005; 112:48–53.
- 187. Zelmanovitz T, Gross JL, Oliveira JR, et al.:** The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. *Diabetes Care* 1997; 20:516.
- 188. Zeeuw Giuseppe Remuzzi, ; Hans-Henrik Parving, ; William F. Keane, ; Zhongxin Zhang, ; Shahnaz Shahinfar, Steve Snapinn, et al,** Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy. *Circulation*. 2004; 110:921-927.
- 189. Zornoff LA, Skali H, Pfeffer MA, et al.** SAVE Investigators. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. *J Am Coll Cardiol* 2002; 39: 1450–1455.